查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751269

美國吸入麻醉市場規模、佔有率、趨勢分析報告：按藥物、應用、最終用途、細分市場預測，2025-2030 年

U.S. Inhalation Anesthesia Market Size, Share & Trends Analysis Report By Drug (Sevoflurane, Desflurane), By Application (Induction, Maintenance), By End Use (Hospitals, ASC), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國吸入麻醉市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，美國吸入麻醉市場規模預計到2030年將達到10.6億美元，預測期內的複合年成長率為6.1%。

市場成長歸因於縮短住院時間和增加外科手術的需求不斷成長。吸入麻醉透過呼吸道輸送麻醉劑，提供更可控、更有效的鎮靜，且經濟高效、安全可靠，與靜脈麻醉相比，可帶來更好的患者預後。

吸入麻醉可產生可逆性的無意識和麻木狀態，是無痛手術的必要手段。它廣泛應用於各種外科手術的全身麻醉，尤其門診病人、兒童以及有針頭恐懼症的患者。吸入麻醉劑也可用於診斷手術，並可用於手術室外的ICU鎮靜、氣喘患者的鎮靜等。此外，氧化亞氮等麻醉劑可在牙科手術中提供適度的鎮靜。

根據美國國家醫學圖書館的數據，美國每年約有4000萬至5000萬例大型手術。吸入麻醉對於癌症診斷和切片檢查至關重要，美國在這些過程中提供舒適感。美國國家癌症研究所估計，2024年美國將新增約2,001,140例癌症病例，其中14,910例為兒童和青少年。癌症發生率的上升預計將推動吸入麻醉的需求，尤其是在兒童和成人癌症治療中。

美國吸入麻醉市場報告重點

  • 根據藥劑，SEVOFLURANE製劑將主導美國吸入麻醉產業，到 2024 年將佔據 75.5% 的最大銷售佔有率。由於其在日間手術中的普及，可以快速實現深度麻醉並縮短恢復時間，因此需求增加。
  • 預計Isoflurane製劑部分在預測期內將顯著成長。
  • 根據應用，維護階段在 2024 年佔據市場主導地位，收入佔有率最大。然而，預計引入階段在預測期內將以顯著的複合年成長率成長。
  • 按最終用途分類，醫院部門在 2024 年佔據美國吸入麻醉行業的最大收益佔有率。
  • 在預計預測期內，門診手術中心 (ASC) 最終用途部分將以 7.0% 的最快複合年成長率成長。
  • 預計未來幾年，ASC 中越來越多的外科手術（包括整形外科、眼科、胃腸病學、泌尿系統、整形外科、泌尿科、婦科和足病學）將推動吸入麻醉的需求。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國吸入麻醉市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章美國吸入麻醉市場：藥物業務分析

  • 2024 年及 2030 年各藥物市場佔有率
  • 藥品細分細分儀表板
  • 市場規模、預測與趨勢分析（按藥物，2018-2030 年）
  • SEVOFLURANE
  • DESFLURANE
  • Isoflurane
  • 其他

第5章美國吸入麻醉市場：應用商業分析

  • 2024 年及 2030 年各應用領域的市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2018-2030 年）
  • 介紹
  • 維護

第6章美國吸入麻醉市場：依最終用途的業務分析

  • 2024 年和 2030 年按最終用途分類的市場佔有率
  • 最終用途細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院
  • 門診手術中心（ASC）
  • 其他

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Baxter
    • AbbVie Inc.
    • Piramal Enterprises Ltd.
    • Hikma Pharmaceuticals PLC
    • Halocarbon, LLC
    • Sandoz Group AG
    • Fresenius Kabi AG
Product Code: GVR-4-68040-570-5

U.S. Inhalation Anesthesia Market Growth & Trends:

The U.S. inhalation anesthesia market size is anticipated to reach USD 1.06 billion by 2030, growing at a CAGR of 6.1% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is attributed to the rising demand for shorter hospital stays and increasing surgical procedures. Inhalation anesthesia offers higher patient outcomes compared to intravenous anesthesia, as administering anesthetic agents through the respiratory tract allows for more controllable, effective sedation that is both cost-effective and safe.

Inhalation anesthesia creates a reversible state of unconsciousness and loss of sensation, making it essential for pain-free surgeries. It is widely used for general anesthesia in various surgical settings, especially in outpatient, pediatric, and needle-phobic patients. Inhalation anesthetics are also valuable in diagnostic procedures and can be utilized outside the operating room for ICU sedation or conditions such as status asthmaticus. In addition, agents such as nitrous oxide provide moderate sedation in dental settings.

According to the National Library of Medicine, around 40 to 50 million major surgeries are conducted annually in the U.S. Inhalation anesthesia is critical for cancer diagnoses and biopsies, offering comfort during these procedures. The National Cancer Institute estimates that in 2024, about 2,001,140 new cancer cases will be diagnosed in the U.S., including 14,910 cases in children and adolescents. This rising cancer incidence is expected to boost the demand for inhalation anesthesia, particularly in pediatric and adult oncology care.

U.S. Inhalation Anesthesia Market Report Highlights:

  • Based on drug, the sevoflurane drug dominated the U.S. inhalation anesthesia industry, accounting for the largest revenue share of 75.5% in 2024. The demand is driven by its popularity in day surgery due to the quick attainment of deep anesthesia and faster recovery times.
  • The isoflurane drug segment is expected to grow significantly over the forecast period.
  • Based on application, the maintenance phase dominated the market with the largest revenue share in 2024. However, the induction phase is expected to grow at a significant CAGR over the forecast period.
  • Based on end use, the hospitals segment led the U.S. inhalation anesthesia industry with the largest revenue share in 2024.
  • The Ambulatory Surgical Centers (ASC) end use segment is expected to grow at the fastest CAGR of 7.0% over the forecast period.
  • The growing number of surgical procedures, including orthopedics, ophthalmology, gastroenterology, ENT, cosmetic surgeries, urology, gynecology, and podiatry, in ASCs is expected to drive the demand for inhalation anesthesia in the coming years.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Inhalation Anesthesia Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Inhalation Anesthesia Market: Service Business Analysis

  • 4.1. Drug Market Share, 2024 & 2030
  • 4.2. Drug Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 4.4. Sevoflurane
    • 4.4.1. Sevoflurane Market, 2018 - 2030 (USD Million)
  • 4.5. Desflurane
    • 4.5.1. Desflurane Market, 2018 - 2030 (USD Million)
  • 4.6. Isoflurane
    • 4.6.1. Isoflurane Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Inhalation Anesthesia Market: Formulation Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Induction
    • 5.4.1. Inhalation Anesthesia Market, for Induction, 2018 - 2030 (USD Million)
  • 5.5. Maintenance
    • 5.5.1. Inhalation Anesthesia Market, for Maintenance, 2018 - 2030 (USD Million)

Chapter 6. U.S. Inhalation Anesthesia Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Inhalation Anesthesia Market, in Hospitals, 2018 - 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers (ASC)
    • 6.5.1. Inhalation Anesthesia Market, in Ambulatory Surgical Centers, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Inhalation Anesthesia Market, in Others, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Baxter
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AbbVie Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Piramal Enterprises Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Hikma Pharmaceuticals PLC
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Halocarbon, LLC
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sandoz Group AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Fresenius Kabi AG
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. inhalation anesthesia market, by drug, 2018 - 2030 (USD Million)
  • Table 4 U.S. inhalation anesthesia market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. inhalation anesthesia market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. inhalation anesthesia market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Drug outlook (USD Million)
  • Fig. 9 Application outlook (USD Million)
  • Fig. 10 End use outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. inhalation anesthesia market dynamics
  • Fig. 13 U.S. inhalation anesthesia market: Porter's five forces analysis
  • Fig. 14 U.S. inhalation anesthesia market: Pestle analysis
  • Fig. 15 U.S. inhalation anesthesia market: Drug segment dashboard
  • Fig. 16 U.S. inhalation anesthesia market: Drug market share analysis, 2024 & 2030
  • Fig. 17 Sevoflurane market, 2018 - 2030 (USD Million)
  • Fig. 18 Desflurane market, 2018 - 2030 (USD Million)
  • Fig. 19 Isoflurane market, 2018 - 2030 (USD Million)
  • Fig. 20 Other drug market, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. inhalation anesthesia market: Application segment dashboard
  • Fig. 22 U.S. inhalation anesthesia market: Application market share analysis, 2024 & 2030
  • Fig. 23 Induction U.S. inhalation anesthesia market, for induction, 2018 - 2030 (USD Million)
  • Fig. 24 Induction U.S. inhalation anesthesia market, for maintenance, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. inhalation anesthesia market: End use segment dashboard
  • Fig. 26 U.S. inhalation anesthesia market: End use market share analysis, 2024 & 2030
  • Fig. 27 Induction U.S. inhalation anesthesia market, in Hospitals, 2018 - 2030 (USD Million)
  • Fig. 28 Induction U.S. inhalation anesthesia market, in Ambulatory Surgical Centers, 2018 - 2030 (USD Million)
  • Fig. 29 Induction U.S. inhalation anesthesia market, in Others, 2018 - 2030 (USD Million)
  • Fig. 30 Company categorization
  • Fig. 31 Company market position analysis
  • Fig. 32 Strategic framework